314 related articles for article (PubMed ID: 33881478)
1. Axillary Pathologic Complete Response After Neoadjuvant Systemic Therapy by Breast Cancer Subtype in Patients With Initially Clinically Node-Positive Disease: A Systematic Review and Meta-analysis.
Samiei S; Simons JM; Engelen SME; Beets-Tan RGH; Classe JM; Smidt ML;
JAMA Surg; 2021 Jun; 156(6):e210891. PubMed ID: 33881478
[TBL] [Abstract][Full Text] [Related]
2. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy.
Barron AU; Hoskin TL; Day CN; Hwang ES; Kuerer HM; Boughey JC
JAMA Surg; 2018 Dec; 153(12):1120-1126. PubMed ID: 30193375
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
[TBL] [Abstract][Full Text] [Related]
4. Rate and predictors of nodal pathological complete response following neoadjuvant endocrine treatment in clinically biopsy-proven node-positive breast cancer patients.
Schipper RJ; de Bruijn A; Voogd AC; Bloemen JG; Van Riet YE; Vriens BEP; Smidt ML; Siesling S; van der Sangen MJC; Nieuwenhuijzen GAP
Eur J Surg Oncol; 2021 Aug; 47(8):1928-1933. PubMed ID: 34030918
[TBL] [Abstract][Full Text] [Related]
5. The diagnostic performance of sentinel lymph node biopsy in pathologically confirmed node positive breast cancer patients after neoadjuvant systemic therapy: A systematic review and meta-analysis.
van Nijnatten TJ; Schipper RJ; Lobbes MB; Nelemans PJ; Beets-Tan RG; Smidt ML
Eur J Surg Oncol; 2015 Oct; 41(10):1278-87. PubMed ID: 26329781
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer.
Simons JM; van Nijnatten TJA; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef C; Sars PRA; Heijmans HJ; van Haaren ERM; Vles WJ; Contant CME; Menke-Pluijmers MBE; Smit LHM; Kelder W; Boskamp M; Koppert LB; Luiten EJT; Smidt ML
JAMA Surg; 2022 Nov; 157(11):991-999. PubMed ID: 36069889
[TBL] [Abstract][Full Text] [Related]
7. Predictors of axillary node response in node-positive patients undergoing neoadjuvant chemotherapy for breast cancer.
Ladak F; Chua N; Lesniak D; Ghosh S; Wiebe E; Yakimetz W; Rajaee N; Olson D; Peiris L
Can J Surg; 2022; 65(1):E89-E96. PubMed ID: 35135785
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Performance of Noninvasive Imaging for Assessment of Axillary Response After Neoadjuvant Systemic Therapy in Clinically Node-positive Breast Cancer: A Systematic Review and Meta-analysis.
Samiei S; de Mooij CM; Lobbes MBI; Keymeulen KBMI; van Nijnatten TJA; Smidt ML
Ann Surg; 2021 Apr; 273(4):694-700. PubMed ID: 33201095
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer: A Systematic Review and Meta-analysis.
Simons JM; van Nijnatten TJA; van der Pol CC; Luiten EJT; Koppert LB; Smidt ML
Ann Surg; 2019 Mar; 269(3):432-442. PubMed ID: 30312200
[TBL] [Abstract][Full Text] [Related]
10. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
[TBL] [Abstract][Full Text] [Related]
11. A model to predict pathologic complete response of axillary lymph nodes to neoadjuvant chemo(immuno)therapy in patients with clinically node-positive breast cancer.
Schipper RJ; Moossdorff M; Nelemans PJ; Nieuwenhuijzen GA; de Vries B; Strobbe LJ; Roumen RM; van den Berkmortel F; Tjan-Heijnen VC; Beets-Tan RG; Lobbes MB; Smidt ML
Clin Breast Cancer; 2014 Oct; 14(5):315-22. PubMed ID: 24548732
[TBL] [Abstract][Full Text] [Related]
12. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial.
Boughey JC; McCall LM; Ballman KV; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Flippo-Morton T; Hunt KK
Ann Surg; 2014 Oct; 260(4):608-14; discussion 614-6. PubMed ID: 25203877
[TBL] [Abstract][Full Text] [Related]
13. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).
Ollila DW; Cirrincione CT; Berry DA; Carey LA; Sikov WM; Hudis CA; Winer EP; Golshan M
J Am Coll Surg; 2017 Apr; 224(4):688-694. PubMed ID: 28089784
[TBL] [Abstract][Full Text] [Related]
14. Predicting breast and axillary response after neoadjuvant treatment for breast cancer: The role of histology vs receptor status.
Vugts G; Van den Heuvel F; Maaskant-Braat AJG; Voogd AC; Van Warmerdam LJC; Nieuwenhuijzen GAP; Van der Sangen MJC
Breast J; 2018 Nov; 24(6):894-901. PubMed ID: 30033607
[TBL] [Abstract][Full Text] [Related]
15. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N
Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive nodal restaging in clinically node positive breast cancer patients after neoadjuvant systemic therapy: a systematic review.
Schipper RJ; Moossdorff M; Beets-Tan RGH; Smidt ML; Lobbes MBI
Eur J Radiol; 2015 Jan; 84(1):41-47. PubMed ID: 25458227
[TBL] [Abstract][Full Text] [Related]
17. Relationship Between Breast and Axillary Pathologic Complete Response in Women Receiving Neoadjuvant Chemotherapy for Breast Cancer.
Lim DW; Greene BD; Look Hong NJ
Ann Surg Oncol; 2021 Oct; 28(10):5495-5506. PubMed ID: 34374914
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer subtypes affect the ultrasound performance for axillary lymph node status evaluation after neoadjuvant chemotherapy: a retrospective analysis.
Fei J; Wang GQ; Meng YY; Zhong X; Ma JZ; Sun NN; Chen JJ
Jpn J Clin Oncol; 2021 Oct; 51(10):1509-1514. PubMed ID: 34345909
[TBL] [Abstract][Full Text] [Related]
19. Axillary ultrasound for prediction of response to neoadjuvant therapy in the context of surgical strategies to axillary dissection in primary breast cancer: a systematic review of the current literature.
Banys-Paluchowski M; Gruber IV; Hartkopf A; Paluchowski P; Krawczyk N; Marx M; Brucker S; Hahn M
Arch Gynecol Obstet; 2020 Feb; 301(2):341-353. PubMed ID: 31897672
[TBL] [Abstract][Full Text] [Related]
20. Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: Time trend, imaging staging power and nodal downstaging according to molecular subtype.
Di Micco R; Zuber V; Fiacco E; Carriero F; Gattuso MI; Nazzaro L; Panizza P; Gianolli L; Canevari C; Di Muzio N; Pasetti M; Sassi I; Zambetti M; Gentilini OD
Eur J Surg Oncol; 2019 Jun; 45(6):969-975. PubMed ID: 30744944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]